New Alzheimer's drug repairs DNA damage and reduces brain inflammation

A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.

This story was reported by Healthy Aging News -- ScienceDaily. EUROPES curates Europe's most relevant coverage — read the full report at the original source.